Your own patent description paper use the word "numerous" anecdotal reports and these two are just another two to add to the list of further anecdotal reports. And many are not reported as well
"Since this time, there have been numerous anecdotal reports of abscopal effects in patients receiving radiotherapy.".....As mentioned, abscopal responses to radiotherapy have generally been observed anecdotally. They are also infrequently reported.
"https://patentscope.wipo.int/search...queryString=FP:(noxopharm)&tab=PCTDescription
and meanwhile there are new studies showed that it is valid but a bit more than 8. In there words "consistently detected".
"In this proof-of-principle clinical trial, Golden and colleagues are the first to demonstrate that abscopal responses can be consistently detected in patients with confirmed solid metastatic cancer treated with radiation therapy and immunotherapy"
"Golden et al. showed that 27% of the patients treated with this regimen demonstrated abscopal responses. Furthermore, those patients who developed an abscopal response had better overall survival (21 vs. 8 months). While there were a diverse set of solid tumor types in the study, the two best represented groups were non-small-cell lung cancer patients and breast cancer patients. The publication is the first reported study to date with long term results that validates the concept of synergistic interactions between radiotherapy, chemotherapy, and GM-CSF." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828732/
So yes it is exciting.....but no where near the "8 plus now 2 more" you are trying to spin as Golden et al are already claiming up to 27% demonstrated abscoopal responses.
NOX Price at posting:
93.0¢ Sentiment: None Disclosure: Not Held
(20min delay)
